SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

Globalstar is trending due to reports that Amazon is in talks to acquire the company, fueling widespread speculation about a potential bidding war involving other major tech players and SpaceX. Community members are actively debating the company's valuation, the strategic value of its spectrum assets in the direct-to-device space, and whether long-term shareholders should hold out for a significant acquisition premium.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors and the online community fixate on the former President's aggressive rhetoric regarding military escalation in Iran, fueling intense debate over his geopolitical strategy and its impact on the markets. While supporters view his strong posture as a necessary display of dominance, critics are actively highlighting contradictions in his messaging and expressing deep concerns over the potential for prolonged conflict and economic instability.

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

Market participants are bracing for volatility surrounding a scheduled prime-time address from President Trump regarding the ongoing conflict in Iran, with the community sharply divided between expectations of a 'buy the rumor, sell the news' event and fears of a deeper escalation involving ground troops. Traders are closely monitoring the potential for significant moves in oil and equity indices as the market attempts to decipher whether the administration is signaling a strategic withdrawal or a major military shift.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk (SNDK) is experiencing extreme volatility driven by shifting sentiment regarding Middle East geopolitical tensions and conflicting narratives over memory sector demand, specifically related to Google's TurboQuant efficiency research. The community remains deeply divided, with bulls pointing to fundamental growth and potential recovery after a steep pullback, while bears argue the recent parabolic run-up was unsustainable and warn of further technical downside.

Launchr is a programmable creator fee engine designed to adapt to every stage of a token’s lifecycle.  Instead of hard coded splits or one time choices, Launchr lets creators dynamically route fees in real time based on market conditions, liquidity depth, and strategy.

Launchr

Investors are actively debating the viability and longevity of the token amidst high-energy launch promotion and community efforts to drive trading volume. While some participants focus on the excitement of early-stage momentum, others are voicing caution regarding the sustainability of these types of market movements.

Iridium Communications, Inc. operates as a commercial provider of communications services offering true global coverage, connecting people, organizations and assets to and from anywhere, in real time. It offers its services to businesses, the U.S. and foreign governments, non-governmental organizations, and consumers via satellite network, which has an architecture of operational satellites with in-orbit spares and related ground infrastructure. Its products include personal communicators, messengers, and trackers, satellite phones, push-to-talk-devices, broadband terminals, midband terminals, external antennas, docking stations, apps, accessories and developer tools & resources. The company was founded in 2000 and is headquartered in McLean, VA.

Iridium Communications Inc

Iridium Communications is currently drawing significant community attention as investors debate its long-term value and competitive positioning against major satellite industry players. Discussions are centered on the company's resilient government and military contracts, its recent acquisition to bolster secure time and location services, and its ongoing stock buyback programs amidst broader sector volatility.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is trending as investors react to the company moving up its earnings report to April 1st, fueling intense speculation about potential surprises or major catalysts. The community remains deeply divided, with bulls highlighting beverage expansion deals and upcoming federal CBD Medicare pilot programs, while vocal critics continue to focus on long-standing frustrations regarding share dilution, leadership, and sector-wide volatility.

VisionWave Holdings, Inc. engages in the forefront of revolutionizing defense capabilities by integrating advanced artificial intelligence (AI) and autonomous solutions across air, ground, and sea domains. The company was founded on March 20, 2024 and is headquartered in Wilmington, DE.

VisionWave Holdings Inc.

VisionWave Holdings, Inc.

VisionWave Holdings is experiencing heightened investor interest driven by recent corporate updates, including strategic partnerships for RF-based defense technology and the expansion of its subsidiary's drone maintenance platform. The community is actively debating the stock's potential for a significant squeeze, citing its low float and heavy institutional ownership, though skeptics remain cautious about the impact of potential share offerings.

Hertz Global Holdings, Inc. engages in the vehicle rental business through the Hertz, Dollar, and Thrifty brands. It operates under the Americas Rental Car (RAC) and International Rental Car (RAC) segments. The Americas RAC segment focuses on operations in the United States, Canada, Latin America, and the Caribbean. The International RAC segment includes the provision of rental and sales of vehicles and value-added services in other locations. The company was founded in 1918 and is headquartered in Estero, FL.

Hertz Global Holdings Inc. - Ordinary Shares (New)

Hertz Global Holdings Inc

Hertz Global Holdings is capturing significant community interest driven by institutional buying, particularly speculation surrounding Bill Ackman's stake and the potential for a short squeeze given the stock's elevated short interest. Traders are closely monitoring the upcoming earnings release and chart consolidation, with active discussions focused on the company's turnaround efforts, fleet management, and the possibility of a major price breakout.

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals is trending as investors monitor the company's progress in expanding its obesity treatment pipeline, particularly following positive trial data and regulatory milestones for its core asset, IMCIVREE. The community remains focused on the potential for strategic M&A activity and the clinical success of upcoming candidates targeting hypothalamic obesity, which many see as a major value-driving catalyst.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lexicon Pharmaceuticals (NASDAQ:LXRX) Trading 8.7% Higher - Time to Buy?

Lexicon Pharmaceuticals (NASDAQ:LXRX) Trading 8.7% Higher - Should You Buy...

Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Passes Above Two Hundred Day Moving Average - Here's Why

Lexicon Pharmaceuticals (NASDAQ:LXRX) Share Price Passes Above 200 Day Moving Average - Should You Sell...

LXRX Stock Up as NVO Initiates Phase I Study of Partnered Obesity Drug

Lexicon Pharmaceuticals stock jumps as NVO launches phase I study of oral obesity candidate LX9851, advancing a promising partnered therapy.

Lexicon Pharmaceuticals' (LXRX) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated a "buy" rating and issued a $6.00 price objective on shares of Lexicon Pharmaceuticals in a report on Monday...

<ul class="summary-bullets"><li>The start of the trial triggered a second $10 million milestone payment to Lexicon.</li><li>The Phase 1 study will evaluate safety and dosing in 96 overweight or obese participants.</li><li>The trial is expected to be completed in early 2027, Novo said.</li></ul>Novo Nordisk (NVO) is pushing deeper into next-gen obesity treatments. The drugmaker announced on Monday that it has initiated a Phase 1 study of LX9851, Lexicon Pharmaceuticals’ oral non-incretin drug candidate for obesity and related metabolic disorders.&nbsp;This adds to Novo’s obesity treatment pipeline, which also features the semaglutide injection, famously known as Wegovy.&nbsp;At the time of writing,&nbsp;<a href="https://stocktwits.com/symbol/NVO">NVO shares</a> climbed 1%, while&nbsp;<a href="https://stocktwits.com/symbol/LXRX">Lexicon Pharmaceuticals’ (LXRX) stock</a> traded over 5% higher.<h2 class="st-heading-2">Novo’s $10 Million Milestone Payment To Lexicon</h2>The start of the trial triggered a second $10 million milestone payment to Lexicon under their licensing deal signed in March 2025. The agreement gives Novo Nordisk exclusive global rights to develop and commercialize the drug, with Lexicon eligible to receive up to $1 billion in total milestone payments, as well as royalties on future sales.The Phase 1 study will evaluate safety and dosing in 96 overweight or obese participants. The trial is expected to be completed in early 2027.“LX9851 offers a novel approach to the treatment of obesity and related metabolic conditions. It is an important addition to our pipeline of potential treatment options as we look to meet the diverse needs of people living with obesity, diabetes and their associated comorbidities,” said Jacob Sten Petersen, Senior Vice President and Head of Global Research at Novo Nordisk.&nbsp;<h2 class="st-heading-2">Lilly’s&nbsp;Experimental Diabetes Pill Outperforms Oral Semaglutide&nbsp;</h2>This comes days after&nbsp;Eli Lilly and Company (LLY) announced that its experimental diabetes pill, Orforglipron, outperformed oral semaglutide in a large Phase 3 study, delivering stronger reductions in blood sugar and greater weight loss over 52 weeks. Lilly has filed the drug for approval in more than 40 countries and plans to submit it in the U.S. later this year.Drug developers are racing to tap the booming obesity market, currently led by injectables like Wegovy and Eli Lilly’s Zepbound.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for NVO and LXRX remained in the ‘bearish’ zone over the past 24 hours.One user called LXRX’s price point “attractive.”<stembedurl>https://stocktwits.com/macrossluvsrobotech/message/648275638</stembedurl>Another user was skeptical about Novo’s forecast.<stembedurl>https://stocktwits.com/Golferhack12/message/648300759</stembedurl>Year-to-date, NVO stock fell 29% while LXRX shares have gained more than 40%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. 

Novo Nordisk Advances Obesity Pipeline With Early-Stage Oral Drug Trial From Lexicon Deal

The trial is part of a licensing deal between Novo and Lexicon that allows Novo to develop and commercialize the drug.

Equity

XENE Stock Up as Azetukalner Meets Goal in Focal Onset Seizures Study

Xenon stock soars after phase III X-TOLE2 shows azetukalner significantly cuts focal onset seizure frequency. The company plans an NDA filing in third-quarter 2026.

Citigroup Forecasts Strong Price Appreciation for Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock

Citigroup lifted their price objective on Lexicon Pharmaceuticals from $2.10 to $2.30 and gave the company a "buy" rating in a report on Tuesday...

What is HC Wainwright's Estimate for LXRX Q1 Earnings?

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) - HC Wainwright issued their Q1 2026 earnings per share estimates for Lexicon Pharmaceuticals in a report issued on Thursday, March 5th. HC...

Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Up 5.8% Following Earnings Beat

Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Up 5.8% Following Earnings Beat...

FY2027 Earnings Forecast for LXRX Issued By HC Wainwright

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) - Stock analysts at HC Wainwright issued their FY2027 EPS estimates for Lexicon Pharmaceuticals in a research report issued on Thursday...

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Lexicon Pharmaceuticals Inc

Thematic ETFs

Prediction Markets

OpenClaw & Agentic-Directed Trading

Tokenization

Recognizing the tool or mechanism that redefined how we trade. From prediction markets to next-gen tech, this award honors the innovation that pushed the boundaries of access and efficiency in modern finance.

LXRX
Lexicon Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LXRX News

LXRXLexicon Pharmaceuticals Inc